| p53-dependent non-coding RNA networks in chronic lymphocytic leukemia CJ Blume, A Hotz-Wagenblatt, J Hüllein, L Sellner, A Jethwa, T Stolz, ... Leukemia 29 (10), 2015 | 182 | 2015 |
| Drug-perturbation-based stratification of blood cancer S Dietrich, M Oleś, J Lu, L Sellner, S Anders, B Velten, B Wu, J Huellein, ... The Journal of clinical investigation 128 (1), 427-445, 2018 | 154 | 2018 |
| Lysosome‐targeting amplifiers of reactive oxygen species as anticancer prodrugs S Daum, MSV Reshetnikov, M Sisa, T Dumych, MD Lootsik, R Bilyy, E Bila, ... Angewandte Chemie International Edition 56 (49), 15545-15549, 2017 | 141 | 2017 |
| Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy S Stock, M Schmitt, L Sellner International journal of molecular sciences 20 (24), 6223, 2019 | 118 | 2019 |
| ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data V Bystry, T Reigl, A Krejci, M Demko, B Hanakova, A Grioni, H Knecht, ... Bioinformatics 33 (3), 435-437, 2017 | 106 | 2017 |
| Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients JM Hoffmann, ML Schubert, L Wang, A Hückelhoven, L Sellner, S Stock, ... Frontiers in immunology 8, 1956, 2018 | 102 | 2018 |
| Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells P Marzenell, H Hagen, L Sellner, T Zenz, R Grinyte, V Pavlov, S Daum, ... Journal of medicinal chemistry 56 (17), 6935-6944, 2013 | 99 | 2013 |
| Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ... Leukemia 32 (3), 774-787, 2018 | 90 | 2018 |
| Improved Synthesis of N-Benzylaminoferrocene-Based Prodrugs and Evaluation of Their Toxicity and Antileukemic Activity S Daum, VF Chekhun, IN Todor, NY Lukianova, YV Shvets, L Sellner, ... Journal of medicinal chemistry 58 (4), 2015-2024, 2015 | 80 | 2015 |
| Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. L Sellner, D Capper, J Meyer, CD Langhans, CM Hartog, H Pfeifer, ... European journal of haematology 85 (5), 457-459, 2010 | 78 | 2010 |
| Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients S Stock, R Übelhart, ML Schubert, F Fan, B He, JM Hoffmann, L Wang, ... International journal of cancer 145 (5), 1312-1324, 2019 | 74 | 2019 |
| Autologous retransplantation for patients with recurrent multiple myeloma: a single‐center experience with 200 patients L Sellner, C Heiss, A Benner, MS Raab, J Hillengass, D Hose, N Lehners, ... Cancer 119 (13), 2438-2446, 2013 | 71 | 2013 |
| Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton PB Knudsen, B Hanna, S Ohl, L Sellner, T Zenz, H Döhner, ... Leukemia 28 (6), 1289-1298, 2014 | 61 | 2014 |
| Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients F Fan, HJ Yoo, S Stock, L Wang, Y Liu, ML Schubert, S Wang, B Neuber, ... International journal of cancer 148 (2), 419-428, 2021 | 54 | 2021 |
| Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT L Sellner, A Boumendil, H Finel, S Choquet, G De Rosa, F Falzetti, ... Bone marrow transplantation 51 (2), 212-218, 2016 | 53 | 2016 |
| Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia A Jethwa, J Hüllein, T Stolz, C Blume, L Sellner, A Jauch, M Sill, AP Kater, ... British journal of haematology 163 (4), 496-500, 2013 | 50 | 2013 |
| MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia B Wu, M Słabicki, L Sellner, S Dietrich, X Liu, A Jethwa, J Hüllein, ... British journal of haematology 179 (3), 421-429, 2017 | 46 | 2017 |
| Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients ML Schubert, A Schmitt, B Neuber, A Hückelhoven-Krauss, A Kunz, ... Blood 134, 51, 2019 | 45 | 2019 |
| Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation ML Schubert, A Hückelhoven, JM Hoffmann, A Schmitt, P Wuchter, ... Human Gene Therapy 27 (10), 758-771, 2016 | 45 | 2016 |
| Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells S Mamidi, S Höne, C Teufel, L Sellner, T Zenz, M Kirschfink Oncoimmunology 4 (3), e979688, 2015 | 44 | 2015 |
